Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$40.16 +1.0%	$35.29	$21.62 ▼ $41.82	$7.63B	1.1	2.49 million shs	575,622 shs
EWTX Edgewise Therapeutics	$14.79 -3.3%	$14.42	$10.60 ▼ $38.12	$1.55B	0.28	1.21 million shs	104,842 shs
LNTH Lantheus	$76.57 -1.6%	$88.82	$73.11 ▼ $126.89	$5.30B	0.11	1.01 million shs	217,317 shs
ROIV Roivant Sciences	$11.10 -2.0%	$10.81	$8.73 ▼ $13.06	$7.54B	1.16	5.58 million shs	1.83 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	0.00%	+3.00%	+17.55%	+20.51%	+42.79%
EWTX Edgewise Therapeutics	0.00%	+0.33%	+3.45%	-42.15%	-12.68%
LNTH Lantheus	0.00%	-4.56%	-4.20%	-24.26%	-1.80%
ROIV Roivant Sciences	0.00%	+0.80%	+4.91%	+4.33%	+5.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.6746 of 5 stars	4.5	2.0	3.9	3.4	3.3	0.6
EWTX Edgewise Therapeutics	2.6649 of 5 stars	4.4	1.0	0.0	1.5	3.3	0.0
LNTH Lantheus	4.2372 of 5 stars	3.5	1.0	4.2	1.6	2.5	1.9
ROIV Roivant Sciences	2.2297 of 5 stars	3.5	3.0	0.0	1.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.92	Moderate Buy	$57.36	42.82% Upside
EWTX Edgewise Therapeutics	2.78	Moderate Buy	$39.78	169.04% Upside
LNTH Lantheus	3.00	Buy	$132.67	73.26% Upside
ROIV Roivant Sciences	3.00	Buy	$17.50	57.73% Upside

Current Analyst Ratings Breakdown

Latest EWTX, ROIV, LNTH, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00
6/5/2025	EWTX Edgewise Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$48.00
5/28/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/8/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $117.00
4/30/2025	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$46.00 ➝ $63.00
4/30/2025	BBIO BridgeBio Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$52.00 ➝ $55.00
4/30/2025	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $72.00
4/30/2025	EWTX Edgewise Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$41.00
4/21/2025	EWTX Edgewise Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$43.00 ➝ $43.00
4/21/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
4/15/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$49.00 ➝ $53.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$127.42M	59.85	N/A	N/A	($7.71) per share	-5.21
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.53 per share	N/A
LNTH Lantheus	$1.54B	3.45	$6.39 per share	11.98	$11.91 per share	6.43
ROIV Roivant Sciences	$29.05M	259.61	N/A	N/A	$7.76 per share	1.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-241.44%	N/A	-75.69%	7/30/2025 (Estimated)
EWTX Edgewise Therapeutics	-$100.16M	-$1.55	N/A	N/A	N/A	N/A	-26.83%	-25.67%	8/6/2025 (Estimated)
LNTH Lantheus	$326.66M	$3.52	12.74	12.13	N/A	28.57%	44.29%	23.52%	7/30/2025 (Estimated)
ROIV Roivant Sciences	$4.35B	-$0.25	N/A	N/A	N/A	-119.54%	-14.05%	-12.81%	8/6/2025 (Estimated)

Latest EWTX, ROIV, LNTH, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/8/2025	Q1 2025	EWTX Edgewise Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	N/A	N/A
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.67	4.67
EWTX Edgewise Therapeutics	N/A	26.35	26.35
LNTH Lantheus	N/A	1.65	1.56
ROIV Roivant Sciences	N/A	37.91	37.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
EWTX Edgewise Therapeutics	N/A
LNTH Lantheus	99.06%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
EWTX Edgewise Therapeutics	23.20%
LNTH Lantheus	1.50%
ROIV Roivant Sciences	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	143.29 million	Optionable
EWTX Edgewise Therapeutics	60	105.20 million	71.86 million	Optionable
LNTH Lantheus	700	69.19 million	68.48 million	Optionable
ROIV Roivant Sciences	860	679.81 million	657.18 million	Optionable

EWTX, ROIV, LNTH, and BBIO Headlines

Recent News About These Companies

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

June 16 at 7:00 AM | globenewswire.com

Roivant Sciences à la conférence Goldman Sachs : focus sur l’exécution stratégique

June 10, 2025 | fr.investing.com

Roivant Sciences Ltd. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04:00 PM

June 10, 2025 | zonebourse.com

GAMMA Investing LLC Has $6.49 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 10, 2025 | marketbeat.com

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

June 9, 2025 | globenewswire.com

Vivek Ramaswamy Sells 547,430 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

June 8, 2025 | americanbankingnews.com

Selon un récent dépôt auprès de la SEC, un initié de Roivant Sciences a vendu des actions pour une valeur de 8 454 808 dollars.

June 7, 2025 | zonebourse.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Vivek Ramaswamy Sells 200,800 Shares

June 7, 2025 | insidertrades.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells $2,246,952.00 in Stock

June 6, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Vivek Ramaswamy Sells 547,430 Shares

June 6, 2025 | marketbeat.com

Roivant Sciences Ltd. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 04:20 PM

June 6, 2025 | zonebourse.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $4,801,302.54 in Stock

June 5, 2025 | marketbeat.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 566,278 Shares of Stock

June 5, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $4,801,302.54 in Stock

June 5, 2025 | insidertrades.com

California State Teachers Retirement System Acquires 37,982 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

June 4, 2025 | marketbeat.com

Jefferies Financial Group Inc. Makes New Investment in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 1, 2025 | marketbeat.com

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $324,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 1, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Trading 5.5% Higher - Here's Why

May 30, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Releases Quarterly Earnings Results, Misses Expectations By $0.15 EPS

May 30, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2024 Earnings Call Transcript

May 30, 2025 | insidermonkey.com

What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings

May 30, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EWTX, ROIV, LNTH, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$40.16 +0.38 (+0.97%)

As of 11:34 AM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Edgewise Therapeutics NASDAQ:EWTX

$14.78 -0.51 (-3.30%)

As of 11:34 AM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Lantheus NASDAQ:LNTH

$76.57 -1.26 (-1.62%)

As of 11:34 AM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$11.10 -0.23 (-1.99%)

As of 11:34 AM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time